Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | OGT | O15294 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26773296 | 0.82 | PDE2A (0.62) | NPSR1RXFP1LMNAKMT2AALDH1A1 | |
| SCHEMBL16925834 | 0.77 | AHR (0.58) | F2CFDNPSR1RXFP1LMNA | |
| SCHEMBL16925861 | 0.77 | AHR (0.53) | F2CFDNPSR1RXFP1LMNA | |
| SCHEMBL26773290 | 0.74 | NPSR1 (0.46) | F2CFDNPSR1RXFP1LMNA | |
| SCHEMBL25992588 | 0.72 | OGT (0.59) | F2CFDNPSR1LMNAKMT2A | |
| SCHEMBL28172746 | 0.71 | F2 (1.00) | F2CFDLMNAKMT2AMAPK1 | |
| SCHEMBL16251 | 0.71 | F2 (1.00) | F2CFDLMNAKMT2AMAPK1 | |
| SCHEMBL29669800 | 0.71 | F2 (1.00) | F2CFDLMNAKMT2AMAPK1 | |
| SCHEMBL26773559 | 0.71 | NPSR1 (0.46) | NPSR1RXFP1LMNAPPARGNCOA2 | |
| SCHEMBL26773294 | 0.71 | NPSR1 (0.46) | NPSR1RXFP1LMNAPPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | F2 4812/4885CFD 4209/4885NPSR1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.